By alcyon|2020-01-16T17:44:56+01:00September 16th, 2020|Financial calendar|Comments Off on First Half 2020 Financial Results
Results from Phase 1b/2 Study of TG4001 with Avelumab in Advanced HPV-Positive Cancers
https://channel.royalcast.com/webcast/transgene/20200722_1/
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster [...]
Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
AACR2020 6010 J. Foloppe et al. AACR 2020 Download the [...]
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a - Transgene PR AACR 3 posters
Annual Shareholders’ Meeting
Assemblée-Générale